
Study Period | 2019 - 2030 |
Base Year For Estimation | 2024 |
Forecast Data Period | 2025 - 2030 |
Historical Data Period | 2019 - 2023 |
Market Size (2025) | USD 0.82 Billion |
Market Size (2030) | USD 1.35 Billion |
CAGR (2025 - 2030) | 10.57 % |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Asia Pacific Apheresis Market Analysis
The Asia Pacific Apheresis Market size is estimated at USD 0.82 billion in 2025, and is expected to reach USD 1.35 billion by 2030, at a CAGR of 10.57% during the forecast period (2025-2030).
The major factors contributing to the growth of the Asia Pacific Apheresis market are increasing disease burden, the rise in demand for Blood Component Technology and associated safety, and technological advancements in the development of new apheresis techniques. However, factors such as high capital investment and costs associated with apheresis procedures are expected to restrain the market.
Apheresis Services have now become a popular mode of treatment for multiple complex immune disorders, and there has been a remarkable change in the scenario pertaining to therapeutic apheresis in Asia-Pacific. With the increasing number of diseases and accident cases, along with technological advancements in Apheresis Equipment, the market studied is expected to experience a boost during the forecast period. Additionally, the rising number of government initiatives, blood donation camps, and increasing awareness about Donor Apheresis are factors responsible for the growth of the market studied. Apheresis technology is expensive. It is also technically and medically demanding.
Asia Pacific Apheresis Market Trends
Neurological Disorders is Expected to Grow with High CAGR in the Indication Segment
The pattern of neurologic diseases in Asia is largely similar to that in Western countries, with cerebrovascular diseases, headache, and epileptic seizures being the most common complaints. The high prevalence of epileptic seizures is contributing to the growth of the APAC Epilepsy Therapeutic Market in the region.
Disease features that are specific to Asia include a high proportion of strokes among the youth, mostly from premature atherosclerosis, a high prevalence of intracranial vs extracranial diseases, the relative commonality of neuromyelitis optica and the optic-spinal form of multiple sclerosis (MS), and high incidences of sex-linked dystonia and Parkinson's disease. Plasmapheresis is one of the well-established therapeutic procedures that is usually used in many neurological autoimmune disorders. It is thought that the effects of plasma exchange occur through the elimination of pathognomonic inflammatory mediators, including autoantibodies, complement components, and cytokines. Most of the neurological disease treatments benefit from therapeutic apheresis procedures such as plasmapheresis, and these effects most likely occur through the removal of harmful pathogenic autoantibodies and associated inflammatory mediators.

Asia Pacific Apheresis Industry Overview
The Asia Pacific Apheresis market is moderately competitive and consists of several major players. In terms of market share, a few major players currently dominate the apheresis market, particularly in the area of Apheresis Devices and equipment. With the increasing prevalence of diseases in the Asia Pacific region, the usage of apheresis and the demand for Apheresis Machines is expected to rise, thereby more players are expected to enter the market. Some of the major players in the market are Asahi Kasei Corporation, B. Braun Melsungen AG, Cerus Corporation, Kaneka Corporation and Terumo Corporation, who offer a wide range of Apheresis Equipment and services.
Asia Pacific Apheresis Market Leaders
-
Asahi Kasei Corporation
-
B. Braun Melsungen AG
-
Cerus Corporation
-
Kaneka Corporation
-
Terumo Corporation
- *Disclaimer: Major Players sorted in no particular order

Asia Pacific Apheresis Industry Segmentation
Apheresis is a medical technique, where the blood of an individual, either a donor or patient, is passed through an apparatus that separates a particular constituent and returns the rest of the blood to the circulatory system. This is an extracorporeal therapy.
By Product | Devices |
Disposables | |
By Indication | Renal Disorders |
Hematological Disorders | |
Neurological Disorders | |
Autoimmune Disorders | |
Other Indications | |
By Procedure | Plasmapheresis |
Plateletpheresis | |
Erythrocytapheresis | |
Leukapheresis | |
Other Procedures | |
Geography | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia Pacific |
Asia Pacific Apheresis Market Research FAQs
How big is the Asia Pacific Apheresis Market?
The Asia Pacific Apheresis Market size is expected to reach USD 0.82 billion in 2025 and grow at a CAGR of 10.57% to reach USD 1.35 billion by 2030.
What is the current Asia Pacific Apheresis Market size?
In 2025, the Asia Pacific Apheresis Market size is expected to reach USD 0.82 billion.
Who are the key players in Asia Pacific Apheresis Market?
Asahi Kasei Corporation, B. Braun Melsungen AG, Cerus Corporation, Kaneka Corporation and Terumo Corporation are the major companies operating in the Asia Pacific Apheresis Market.
What years does this Asia Pacific Apheresis Market cover, and what was the market size in 2024?
In 2024, the Asia Pacific Apheresis Market size was estimated at USD 0.73 billion. The report covers the Asia Pacific Apheresis Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Asia Pacific Apheresis Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
APAC Apheresis Industry Report
Statistics for the 2025 Asia Pacific Apheresis market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia Pacific Apheresis analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.